Lilly lifts 2026 guidance on strong Mounjaro and Zepbound momentum
Aug 5, 2026, 6:47 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Strong revenue growth, raised full-year guidance, and multiple regulatory/pipeline catalysts imply near-term upside potential. While IPR&D charges compress GAAP metrics, non-GAAP economics and cash-flow trajectory remain positive, supporting multiple expansion. Historical parallels include post-earnings raises when growth drivers and pipeline progress align with higher guidance, though dilution from acquisitions can temper sentiment in the near term.
AI summary
What happened, with direct paths to the underlying reporting
Lilly posted a robust Q2 2026 with revenue of $22.97B (+48% YoY) and EPS of $7.94 (GAAP) / $8.38 (non-GAAP), aided by $3.03B of acquired IPR&D charges. The company raised 2026 revenue guidance to $85–$87B and non-GAAP EPS to $35.50–$36.50, offset by the IPR&D costs. Regulatory wins and a busy BD pipeline, plus retatrutide obesity data and significant manufacturing expansion in Indiana, support durable growth and potentially higher valuation ahead.
Q2 2026 revenue $22,974M, +48% YoY, led by Mounjaro and Zepbound.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
A new study suggests staying on low starter doses of GLP-1 obesity therapies yields weight loss with notably less nausea than higher doses. This could influence prescribing patter…
Eli Lilly and Merida Biosciences announced a definitive agreement for Lilly to acquire Merida for up to $2.875 billion in cash, with closing expected in Q4 2026. MER511 data in Ph…
Eli Lilly’s Mounjaro received FDA approval to lower major cardiovascular events in adults with type 2 diabetes at high risk. The SURPASS-CVOT trial, the largest head-to-head cardi…
The FDA cleared Roche and Eli Lilly's blood test to identify signs of Alzheimer's in adults aged 55 and older with cognitive decline. The milestone could accelerate commercializat…
